ORIC Pharmaceuticals Announces Multiple Clinical Collaborations for Evaluating ORIC-944 + AR Inhibitors for the Treatment of Prostate Cancer July 23, 2024
FAILED TRIAL: Ph 3 TiNivo-2 didn’t meet primary endpoint from rechallenging RCC patients with immunotherapy after receiving ICI beyond progression on previous ICIs July 23, 2024
Positive Interim Ph 2 Monotherapy Expansion Data for IDE397 in MTAP-Deletion Urothelial and Lung Cancer Announced July 17, 2024
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat for the Treatment of Metastatic CRPC July 9, 2024
Ubix Therapeutics and Yuhan Announce Exclusive License Agreement for UBX-103 for Treatment of Metastatic CRPC July 9, 2024
CHMP adopts positive opinion for BALVERSA (erdafitinib) in unresectable/metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations July 9, 2024
FDA Granted Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic CRPC July 9, 2024
Imfinzi demonstrated statistically significant and clinically meaningful improvement in EFS and OS for MIBC in NIAGARA Ph 3 trial July 1, 2024
First-Patient-In Announced for Ph 1 Trial of IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer July 1, 2024
New Efficacy Data For RCC From KEYNOTE-B61 Added To Lenvima® (Lenvatinib) US Label Supporting Keytruda + Lenvima Indication For The 1L Treatment July 1, 2024
Unprecedented 82.3% DOR at 12 Months in the ENVISION Trial Investigating UGN-102 as a Non-Surgical Treatment for LG-IR-NMIBC announced June 18, 2024
FDA Approved Ph 2/3 Study of KPG-121 + Abiraterone combination as 1L Treatment for metastatic CRPC June 11, 2024
FAILED TRIAL: Confirmatory Ph 3 TROPiCS-04 study in locally advanced/metastatic urothelial cancer (mUC) did not meet the primary endpoint of OS in the ITT population June 4, 2024
European Commission Approves Opdivo, Cisplatin and Gemcitabine combo for the 1L Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma June 4, 2024
MHRA approves expansion of ModiFY trial; Modi-1 to be assessed in RCC in combination with double CPIs May 31, 2024
5 patients deaths reported the next day after update provided on Interim TAMARACK Ph 2 Study Data May 15, 2024
FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer May 15, 2024
